The effectiveness of immune checkpoint inhibitor (ICI) therapy is critically dependent on the expansion of T cells and the subsequent increase in infiltration of precursor-exhausted CD8+ T cells within the tumor (32), and there is potential to further reduce T cell exhaustion by targeting SEMA4D and thereby synergistically promote the effectiveness of ICI therapy. The gene discussed is SEMA4D; the disease is neoplasm.